Professor David A Lane

Publications


Journals

  • Andersson HM; Siegerink B; Luken BM; Crawley JT; Algra A; Lane DA; Rosendaal FR. (9 Feb 2012). High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 119:1555-1560. DOI.
  • Ahnstrom J; Andersson HM; Canis K; Norstrom E; Yu Y; Dahlback B; Panico M; Morris HR; et alCrawley JTB; Lane DA. (1 Jul 2011). Activated protein S cofactor function of protein S: a novel function for a gamma-carboxyglutamic acid residue. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 9:14-14. Author weblink.
  • Xiang Y; de Groot R; Crawley JT; Lane DA. (12 Jul 2011). Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc Natl Acad Sci U S A. 108:11602-11607. DOI.
  • Crawley JT; de Groot R; Xiang Y; Luken BM; Lane DA. (22 Sep 2011). Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 118:3212-3221. DOI.
  • Ahnström J; Andersson HM; Canis K; Norstrøm E; Yu Y; Dahlbäck B; Panico M; Morris HR; et alCrawley JT; Lane DA. (16 Jun 2011). Activated protein C cofactor function of protein S: a novel role for a γ-carboxyglutamic acid residue. Blood. 117:6685-6693. DOI.
  • Greaves M; Lane DA. (1 Sep 2010). Aspiring for quality and service. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 8:1885-1885. DOI.
  • de Groot R; Lane DA; Crawley JT. (21 Oct 2010). The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. Blood. 116:3064-3072. DOI.
  • McKinnon TA; Goode EC; Birdsey GM; Nowak AA; Chan AC; Lane DA; Laffan MA. (29 Jul 2010). Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor. Blood. 116:640-648. DOI.
  • Luken BM; Winn LY; Emsley J; Lane DA; Crawley JT. (10 Jun 2010). The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function. Blood. 115:4910-4913. DOI.
  • Andersson HM; Arantes MJ; Crawley JT; Luken BM; Tran S; Dahlbäck B; Lane DA; Rezende SM. (10 Jun 2010). Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain. Blood. 115:4878-4885. DOI.
  • Greaves M; Lane DA. (1 Jan 2010). Rewards for commitment and success. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 8:1-1. Author weblink DOI.
  • Pos W; Crawley JT; Fijnheer R; Voorberg J; Lane DA; Luken BM. (25 Feb 2010). An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood. 115:1640-1649. DOI.
  • Zanardelli S; Chion AC; Groot E; Lenting PJ; McKinnon TA; Laffan MA; Tseng M; Lane DA. (24 Sep 2009). A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood. 114:2819-2828. DOI.
  • de Groot R; Bardhan A; Ramroop N; Lane DA; Crawley JT. (28 May 2009). Essential role of the disintegrin-like domain in ADAMTS13 function. Blood. 113:5609-5616. DOI.
  • Gardner MD; Chion CK; de Groot R; Shah A; Crawley JT; Lane DA. (29 Jan 2009). A functional calcium-binding site in the metalloprotease domain of ADAMTS13. Blood. 113:1149-1157. DOI.
  • Greaves M; Lane DA; Rosendaal FR. (1 Jan 2009). On the reporting of clinical trials. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 7:1-1. Author weblink DOI.
  • de Groot R; Lane DA. (1 Sep 2008). Shear tango: dance of the ADAMTS13/VWF complex. BLOOD. 112:1548-1549. Author weblink DOI.
  • Crawley JTB; Lane DA; Woodward M; Rumley A; Lowe GDO. (1 Apr 2008). Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 6:583-588. Author weblink DOI.
  • McKinnon TA; Chion AC; Millington AJ; Lane DA; Laffan MA. (15 Mar 2008). N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 111:3042-3049. DOI.
  • Crawley JTB; Lane DA. (1 Feb 2008). The haemostatic role of tissue factor pathway inhibitor. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 28:233-242. Author weblink DOI.
  • Camilleri RS; Cohen H; Mackie IJ; Scully M; Starke RD; Crawley JTB; Lane DA; Machin SJ. (1 Feb 2008). Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 6:331-338. DOI.
  • Greaves M; Lane DA. (1 Jan 2008). Building on strength. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 6:1-1. Author weblink.
  • Crawley JTB; Zanardelli S; Chion CKNK; Lane DA. (1 Jul 2007). The central role of thrombin in hemostasis. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 5:95-101. Author weblink DOI.
  • Villegas-Mendez A; Montes R; Ambrose LR; Warrens AN; Laffan M; Lane DA. (May 2007). Proteolysis of the endothelial cell protein C receptor by neutrophil proteinase 3. J Thromb Haemost. 5:980-988. DOI.
  • Lam JK; Chion CK; Zanardelli S; Lane DA; Crawley JT. (May 2007). Further characterization of ADAMTS-13 inactivation by thrombin. J Thromb Haemost. 5:1010-1018. DOI.
  • Greaves M; Lane DA. (1 Mar 2007). Testimony and new challenges. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 5:448-449. Author weblink DOI.
  • Chion CK; Doggen CJ; Crawley JT; Lane DA; Rosendaal FR. (1 Mar 2007). ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 109:1998-2000. DOI.
  • Castaman G; Biguzzi E; Razzari C; Tosetto A; Fontana G; Asti D; Brancaccio V; Castori D; et alLane DA; Faioni EM. (1 Jan 2007). Association of protein S p.Pro667Pro dimorphism with plasma protein S levels in normal individuals and patients with inherited protein S deficiency. THROMBOSIS RESEARCH. 120:421-426. Author weblink DOI.
  • Preston RJ; Ajzner E; Razzari C; Karageorgi S; Dua S; Dahlbäck B; Lane DA. (29 Sep 2006). Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem. 281:28850-28857. DOI.
  • Persson KE; Stenflo J; Linse S; Stenberg Y; Preston RJ; Lane DA; Rezende SM. (5 Sep 2006). Binding of calcium to anticoagulant protein S: role of the fourth EGF module. Biochemistry. 45:10682-10689. DOI.
  • Mollica LR; Crawley JT; Liu K; Rance JB; Cockerill PN; Follows GA; Landry JR; Wells DJ; et alLane DA. (15 Aug 2006). Role of a 5'-enhancer in the transcriptional regulation of the human endothelial cell protein C receptor gene. Blood. 108:1251-1259. DOI.
  • Mollica L; Preston RJ; Chion AC; Lees SJ; Collins P; Lewis S; Lane DA. (Feb 2006). Autoantibodies to thrombin directed against both of its cryptic exosites. Br J Haematol. 132:487-493. DOI.
  • Zanardelli S; Crawley JT; Chion CK; Lam JK; Preston RJ; Lane DA. (20 Jan 2006). ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem. 281:1555-1563. DOI.
  • Lane DA; Philippou H; Huntington JA. (15 Oct 2005). Directing thrombin. Blood. 106:2605-2612. DOI.
  • O'Donnell JS; McKinnon TA; Crawley JT; Lane DA; Laffan MA. (15 Sep 2005). Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood. 106:1988-1991. DOI.
  • White SJ; Simmonds RE; Lane DA; Baker AH. (1 Jul 2005). Efficient isolation of peptide ligands for the endothelial cell protein C receptor (EPCR) using candidate receptor phage display biopanning. PEPTIDES. 26:1264-1269. Author weblink DOI.
  • Crawley JT; Lam JK; Rance JB; Mollica LR; O'Donnell JS; Lane DA. (1 Feb 2005). Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 105:1085-1093. DOI.
  • Biguzzi E; Razzari C; Lane DA; Castaman G; Cappellari A; Bucciarelli P; Fontana G; Margaglione M; et alD'Andrea G; Simmonds RE; Rezende SM; Preston R; Prisco D; Faioni EM. (1 Jan 2005). Molecular diversity and thrombotic risk in Protein S deficiency: The PROSIT study. HUMAN MUTATION. 25:259-269. Author weblink DOI.
  • Preston RJ; Villegas-Mendez A; Sun YH; Hermida J; Simioni P; Philippou H; Dahlbäck B; Lane DA. (Jan 2005). Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation. FEBS J. 272:97-108. DOI.
  • Preston RJS; Lane DA. (15 Sep 2004). APC stripped bare. BLOOD. 104:1595-1596. Author weblink DOI.
  • Hurtado V; Montes R; Gris JC; Bertolaccini ML; Alonso A; Martínez-González MA; Khamashta MA; Fukudome K; et alLane DA; Hermida J. (1 Sep 2004). Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood. 104:1369-1374. DOI.
  • Rezende SM; Simmonds RE; Lane DA. (15 Feb 2004). Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood. 103:1192-1201. DOI.
  • Mollica L; Lane DA. (Feb 2004). Genetic studies in complex disease. J Thromb Haemost. 2:342-343.
  • Philippou H; Rance J; Myles T; Hall SW; Ariens RA; Grant PJ; Leung L; Lane DA. (22 Aug 2003). Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation. Competition for cofactor sites on thrombin determines its fate. J Biol Chem. 278:32020-32026. DOI.
  • Rance JB; Follows GA; Cockerill PN; Bonifer C; Lane DA; Simmonds RE. (1 Jun 2003). Regulation of the human endothelial cell protein C receptor gene promoter by multiple Sp1 binding sites. Blood. 101:4393-4401. DOI.
  • Raja SM; Chhablani N; Swanson R; Thompson E; Laffan M; Lane DA; Olson ST. (18 Apr 2003). Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. J Biol Chem. 278:13688-13695. DOI.
  • Mille-Baker B; Rezende SM; Simmonds RE; Mason PJ; Lane DA; Laffan MA. (15 Feb 2003). Deletion or replacement of the second EGF-like domain of protein S results in loss of APC cofactor activity. Blood. 101:1416-1418. DOI.
  • Rezende SM; Lane DA; Mille-Baker B; Samama MM; Conard J; Simmonds RE. (15 Oct 2002). Protein S Gla-domain mutations causing impaired Ca(2+)-induced phospholipid binding and severe functional protein S deficiency. Blood. 100:2812-2819. DOI.
  • Lane DA; Mollica LR. (Sep 2002). Haemostatic gene polymorphisms in venous and arterial thrombosis. Pathophysiol Haemost Thromb. 32:213-215. DOI.
  • Kunz G; Ohlin AK; Adami A; Zöller B; Svensson P; Lane DA. (15 May 2002). Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function. Blood. 99:3646-3653.
  • Rezende SM; Lane DA; Zöller B; Mille-Baker B; Laffan M; Dalhbäck B; Simmonds RE. (Feb 2002). Genetic and phenotypic variability between families with hereditary protein S deficiency. Thromb Haemost. 87:258-265.
  • Kuhle S; Lane DA; Jochmanns K; Male C; Quehenberger P; Lechner K; Pabinger I. (Oct 2001). Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost. 86:1007-1011.
  • Simmonds RE; Lane DA. (Oct 2001). The endothelial cell protein C receptor: a candidate genetic risk factor for thrombosis. Thromb Haemost. 86:939-941.
  • Simmonds RE; Hermida J; Rezende SM; Lane DA. (Jul 2001). Haemostatic genetic risk factors in arterial thrombosis. Thromb Haemost. 86:374-385.
  • Chambers JC; Ireland H; Thompson E; Reilly P; Obeid OA; Refsum H; Ueland P; Lane DA; et alKooner JS. (Nov 2000). Methylenetetrahydrofolate reductase 677 C-->T mutation and coronary heart disease risk in UK Indian Asians. Arterioscler Thromb Vasc Biol. 20:2448-2452.
  • Warner D; Catto A; Kunz G; Ireland H; Grant PJ; Lane DA. (1 Sep 2000). The thrombomodulin gene mutation G(127)-> A (Ala25Thr) and cerebrovascular disease. CEREBROVASCULAR DISEASES. 10:359-363. Author weblink DOI.
  • Ariens RAS; Philippou H; Nagaswami C; Weisel JW; Lane DA; Grant PJ. (1 Aug 2000). The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. BLOOD. 96:988-995. Author weblink.
  • Philippou H; Adami A; Davidson SJ; Pepper JR; Burman JF; Lane DA. (Jul 2000). Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass. Thromb Haemost. 84:124-128.
  • Lane DA; Grant PJ. (1 Mar 2000). Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 95:1517-1532.
  • Al-Obaidi MK; Philippou H; Stubbs PJ; Adami A; Amersey R; Noble MM; Lane DA. (1 Feb 2000). Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation. 101:372-377.
  • Kunz G; Ireland HA; Stubbs PJ; Kahan M; Coulton GC; Lane DA. (15 Jan 2000). Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. Blood. 95:569-576.
  • Simmonds RE; Lane DA. (15 Jul 1999). Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: comparison with the structure of CD1/major histocompatibility complex alpha1 and alpha2 domains. Blood. 94:632-641.
  • Bayston TA; Tripodi A; Mannucci PM; Thompson E; Ireland H; Fitches AC; Hananeia L; Olds RJ; et alLane DA. (15 Jun 1999). Familial overexpression of beta antithrombin caused by an Asn135Thr substitution. Blood. 93:4242-4247.
  • Philippou H; Davidson SJ; Mole MT; Pepper JR; Burman JF; Lane DA. (Feb 1999). Two-chain factor VIIa generated in the pericardium during surgery with cardiopulmonary bypass : relationship to increased thrombin generation and heparin concentration. Arterioscler Thromb Vasc Biol. 19:248-254.
  • Fitches AC; Appleby R; Lane DA; De Stefano V; Leone G; Olds RJ. (15 Dec 1998). Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. BLOOD. 92:4671-4676. Author weblink.
  • Doggen CJM; Kunz G; Rosendaal FR; Lane DA; Vos HL; Stubbs PJ; Cats VM; Ireland H. (1 Nov 1998). A mutation in the thrombomodulin gene, (127)G to a coding for Ala25Thr, and the risk of myocardial infarction in men. THROMBOSIS AND HAEMOSTASIS. 80:743-748. Author weblink.
  • Simmonds RE; Ireland H; Lane DA; Zoller B; de Frutos PG; Dahlback B. (1 Jan 1998). Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. ANNALS OF INTERNAL MEDICINE. 128:8-+. Author weblink.
  • Nevard CHF; Jurd KM; Lane DA; Philippou H; Haycock GB; Hunt BJ. (1 Dec 1997). Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome. THROMBOSIS AND HAEMOSTASIS. 78:1450-1455. Author weblink.
  • Bayston TA; Lane DA. (Jul 1997). Antithrombin: molecular basis of deficiency. Thromb Haemost. 78:339-343.
  • vanBoven HH; Lane DA. (1 Jul 1997). Antithrombin and its inherited deficiency states. SEMINARS IN HEMATOLOGY. 34:188-204. Author weblink.
  • Ireland H; Kunz G; Kyriakoulis K; Stubbs PJ; Lane DA. (1 Jul 1997). Thrombomodulin gene mutations associated with myocardial infarction. Circulation. 96:15-18.
  • Simmonds RE; Zöller B; Ireland H; Thompson E; de Frutos PG; Dahlbäck B; Lane DA. (15 Jun 1997). Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood. 89:4364-4370.
  • Woodward M; Lowe GDO; Rumley A; TunstallPedoe H; Philippou H; Lane DA; Morrison CE. (1 Jun 1997). Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey .2. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. BRITISH JOURNAL OF HAEMATOLOGY. 97:785-797. Author weblink DOI.
  • Gandrille S; Borgel D; Ireland H; Lane DA; Simmonds R; Reitsma PH; Mannhalter C; Pabinger I; et alSaito H; Suzuki K; Formstone C; Cooper DN; Espinosa Y; Sala N; Bernardi F; Alach M. (1 Jun 1997). Protein S deficiency: A database of mutations - For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. THROMBOSIS AND HAEMOSTASIS. 77:1201-1214. Author weblink.
  • Lowe GDO; Rumley A; Woodward M; Morrison CE; Philippou H; Lane DA; TunstallPedoe H. (1 Jun 1997). Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey .1. Illustrative reference ranges by age, sex and hormone use. BRITISH JOURNAL OF HAEMATOLOGY. 97:775-784. Author weblink DOI.
  • Mukherjee M; Scully MF; Kakkar VV; Philippou H; Lane DA; Jewitt D. (1 Apr 1997). Decrease in factor VII coagulant activity during percutaneous transluminal coronary angioplasty by heparin-mediated lipolytic action. THROMBOSIS AND HAEMOSTASIS. 77:675-678. Author weblink.
  • Philippou H; Adami A; Amersey RA; Stubbs PJ; Lane DA. (1 Feb 1997). A novel specific immunoassay for plasma two-chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes. Blood. 89:767-775.
  • Lane DA; Bayston T; Olds RJ; Fitches AC; Cooper DN; Millar DS; Jochmans K; Perry DJ; et alOkajima K; Thein SL; Emmerich J. (Jan 1997). Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 77:197-211.
  • Lane DA; Mannucci PM; Bauer KA; Bertina RM; Bochkov NP; Boulyjenkov V; Chandy M; Dahlback B; et alGinter EK; Miletich JP; Rosendaal FR; Seligsohn U. (1 Dec 1996). Inherited thrombophilia .2. THROMBOSIS AND HAEMOSTASIS. 76:824-834. Author weblink.
  • Simmonds RE; Ireland H; Kunz G; Lane DA; Bhavnani M; Castaman G; Hambley H; Laffan M; et alOConnor N; Sas G; Tew CJ; Walker ID. (1 Dec 1996). Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis. BLOOD. 88:4195-4204. Author weblink.
  • Ireland H; Thompson E; Lane DA. (Dec 1996). Gene mutations in 21 unrelated cases of phenotypic heterozygous protein C deficiency and thrombosis. Protein C Study Group. Thromb Haemost. 76:867-873.
  • Lane DA; Mannucci PM; Bauer KA; Bertina RM; Bochkov NP; Boulyjenkov V; Chandy M; Dahlback B; et alGinter EK; Miletich JP; Rosendaal FR; Seligsohn U. (1 Nov 1996). Inherited thrombophilia .1. THROMBOSIS AND HAEMOSTASIS. 76:651-662. Author weblink.
  • Lane DA; Auberger K; Ireland H; Roscher AA; Thein SL. (Sep 1996). Prenatal diagnosis in combined antithrombin and factor V gene mutation. Br J Haematol. 94:753-755.
  • Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA. (Jul 1996). High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost. 76:23-28.
  • Lane DA; Kunz G; Olds RJ; Thein SL. (Jun 1996). Molecular genetics of antithrombin deficiency. Blood Rev. 10:59-74.
  • Rintelen C; Mannhalter C; Ireland H; Lane DA; Knobl P; Lechner K; Pabinger I. (1 May 1996). Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. BRITISH JOURNAL OF HAEMATOLOGY. 93:487-490. Author weblink DOI.
  • Ireland H; Kyriakoulis K; Kunz G; Lane DA. (1 Jan 1996). Directed search for thrombomodulin gene mutations. HAEMOSTASIS. 26:227-232. Author weblink.
  • vanBoven HH; Reitsma PH; Rosendaal FR; Bayston TA; Chowdhury V; Bauer KA; Scharrer I; Conard J; et alLane DA. (1 Mar 1996). Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. THROMBOSIS AND HAEMOSTASIS. 75:417-421. Author weblink.
  • Ireland HA; Boisclair MD; Taylor J; Thompson E; Thein SL; Girolami A; De Caterina M; Scopacasa F; et alDe Stefano V; Leone G; Finazzi G; Cohen H; Lane DA. (1996). Two novel (R(-11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindreds. Hum Mutat. 7:176-179. DOI.
  • DESTEFANO V; MASTRANGELO S; PACIARONI K; IRELAND H; LANE DA; SCIRPA P; BIZZI B; LEONE G. (1 Aug 1995). THROMBOTIC RISK DURING PREGNANCY AND PUERPERIUM IN WOMEN WITH APC-RESISTANCE - EFFECTIVE SUBCUTANEOUS HEPARIN-PROPHYLAXIS IN A PREGNANT PATIENT. THROMBOSIS AND HAEMOSTASIS. 74:793-794. Author weblink.
  • CATTO A; CARTER A; IRELAND H; BAYSTON TA; PHILIPPOU H; BARRETT J; LANE DA; GRANT PJ. (1 Jun 1995). FACTOR-V LEIDEN GENE MUTATION AND THROMBIN GENERATION IN RELATION TO THE DEVELOPMENT OF ACUTE STROKE. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 15:783-785. Author weblink.
  • Philippou H; Adami A; Boisclair MD; Lane DA. (Jun 1995). An ELISA for factor X activation peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass. Br J Haematol. 90:432-437.
  • IRELAND H; BAYSTON T; THOMPSON E; ADAMI A; GONCALVES C; LANE DA; FINAZZI G; BARBUI T. (1 Apr 1995). APPARENT HETEROZYGOUS TYPE-II PROTEIN-C DEFICIENCY CAUSED BY THE FACTOR-V-506 ARG-TO-GLN MUTATION. THROMBOSIS AND HAEMOSTASIS. 73:731-732. Author weblink.
  • CHOWDHURY V; MILLE B; OLDS RJ; LANE DA; WATTON J; BARROWCLIFFE TW; PABINGER I; WOODCOCK BE; et alTHEIN SL. (1 Mar 1995). ANTITHROMBINS SOUTHPORT (LEU 99 TO VAL) AND VIENNA (GIN 118 TO PRO) - 2 NOVEL ANTITHROMBIN VARIANTS WITH ABNORMAL HEPARIN-BINDING. BRITISH JOURNAL OF HAEMATOLOGY. 89:602-609. Author weblink DOI.
  • TROSSAERT M; CONARD J; HORELLOU MH; SAMAMA NM; IRELAND H; BAYSTON TA; LANE DA. (17 Dec 1994). MODIFIED APC RESISTANCE ASSAY FOR PATIENTS ON ORAL ANTICOAGULANTS. LANCET. 344:1709-1709. Author weblink DOI.
  • VANBOVEN HH; OLDS RJ; THEIN SL; REITSMA PH; LANE DA; BRIET E; VANDENBROUCKE JP; ROSENDAAL FR. (15 Dec 1994). HEREDITARY ANTITHROMBIN DEFICIENCY - HETEROGENEITY OF THE MOLECULAR-BASIS AND MORTALITY IN DUTCH FAMILIES. BLOOD. 84:4209-4213. Author weblink.
  • Mille B; Watton J; Barrowcliffe TW; Mani JC; Lane DA. (25 Nov 1994). Role of N- and C-terminal amino acids in antithrombin binding to pentasaccharide. J Biol Chem. 269:29435-29443.
  • Burman JF; Chung HI; Lane DA; Philippou H; Adami A; Lincoln JC. (29 Oct 1994). Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet. 344:1192-1193.
  • Lane DA; Olds RJ; Thein SL. (Sep 1994). Antithrombin III: summary of first database update. Nucleic Acids Res. 22:3556-3559.
  • CHOWDHURY V; LANE DA; MILLE B; AUBERGER K; GANDENBERGERBACHEM S; PABINGER I; OLDS RJ; THEIN SL. (1 Aug 1994). HOMOZYGOUS ANTITHROMBIN DEFICIENCY - REPORT OF 2 NEW CASES (99-LEU TO PHE) ASSOCIATED WITH ARTERIAL AND VENOUS THROMBOSIS. THROMBOSIS AND HAEMOSTASIS. 72:198-202. Author weblink.
  • Dubrey SW; Reaveley DR; Seed M; Lane DA; Ireland H; O'Donnell M; O'Connor B; Noble MI; et alLeslie RD. (Jun 1994). Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes. 43:831-835.
  • OLDS RJ; LANE DA; THEIN SL. (1 Jun 1994). THE MOLECULAR-GENETICS OF ANTITHROMBIN DEFICIENCY. BRITISH JOURNAL OF HAEMATOLOGY. 87:221-226. Author weblink.
  • DAWES J; JAMES K; LANE DA. (12 Apr 1994). CONFORMATIONAL CHANGE IN ANTITHROMBIN INDUCED BY HEPARIN, PROBED WITH A MONOCLONAL-ANTIBODY AGAINST THE 1C/4B REGION. BIOCHEMISTRY. 33:4375-4383. Author weblink DOI.
  • GRAY E; CESMELI S; LORMEAU JC; DAVIES AB; LANE DA. (1 Feb 1994). LOW-AFFINITY HEPARIN IS AN ANTITHROMBOTIC AGENT. THROMBOSIS AND HAEMOSTASIS. 71:203-207. Author weblink.
  • OLDS RJ; LANE DA; CHOWDHURY V; SAS G; PABINGER I; AUBERGER K; THEIN SL. (1 Jan 1994). (ATT) TRINUCLEOTIDE REPEATS IN THE ANTITHROMBIN GENE AND THEIR USE IN DETERMINING THE ORIGIN OF REPEATED MUTATIONS. HUMAN MUTATION. 4:31-41. Author weblink DOI.
  • OLDS RJ; LANE DA; MILLE B; CHOWDHURY V; THEIN SL. (1 Jan 1994). ANTITHROMBIN - THE PRINCIPAL INHIBITOR OF THROMBIN. SEMINARS IN THROMBOSIS AND HEMOSTASIS. 20:353-372. Author weblink DOI.
  • Lane DA; Bowry SK. (1994). The scientific basis for selection of measures of thrombogenicity. Nephrol Dial Transplant. 9 Suppl 2:18-28.
  • Boisclair MD; Lane DA; Philippou H; Esnouf MP; Sheikh S; Hunt B; Smith KJ. (1 Dec 1993). Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood. 82:3350-3357.
  • Boisclair MD; Philippou H; Lane DA. (Dec 1993). Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. Blood Coagul Fibrinolysis. 4:1007-1021.
  • Lane DA; Olds RJ; Boisclair M; Chowdhury V; Thein SL; Cooper DN; Blajchman M; Perry D; et alEmmerich J; Aiach M. (2 Aug 1993). Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 70:361-369.
  • Boisclair MD; Lane DA; Philippou H; Sheikh S; Hunt B. (2 Aug 1993). Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2. Thromb Haemost. 70:253-258.
  • CHOWDHURY V; OLDS RJ; LANE DA; CONARD J; PABINGER I; RYAN K; BAUER KA; BHAVNANI M; et alABILDGAARD U; FINAZZI G; CASTAMAN G; MANNUCCI PM; THEIN SL. (1 Aug 1993). IDENTIFICATION OF 9 NOVEL MUTATIONS IN TYPE-I ANTITHROMBIN DEFICIENCY BY HETERODUPLEX SCREENING. BRITISH JOURNAL OF HAEMATOLOGY. 84:656-661. Author weblink DOI.
  • WATTON J; LONGSTAFF C; LANE DA; BARROWCLIFFE TW. (20 Jul 1993). HEPARIN-BINDING AFFINITY OF NORMAL AND GENETICALLY-MODIFIED ANTITHROMBIN-III MEASURED USING A MONOCLONAL-ANTIBODY TO THE HEPARIN-BINDING SITE OF ANTITHROMBIN-III. BIOCHEMISTRY. 32:7286-7293. Author weblink DOI.
  • LANE DA; ADAMS L. (8 Jul 1993). NON-ANTICOAGULANT USES OF HEPARIN. NEW ENGLAND JOURNAL OF MEDICINE. 329:129-130. Author weblink DOI.
  • OLDS RJ; LANE DA; CHOWDHURY V; DESTEFANO V; LEONE G; THEIN SL. (27 Apr 1993). COMPLETE NUCLEOTIDE-SEQUENCE OF THE ANTITHROMBIN GENE - EVIDENCE FOR HOMOLOGOUS RECOMBINATION CAUSING THROMBOPHILIA. BIOCHEMISTRY. 32:4216-4224. Author weblink DOI.
  • OLDS RJ; LANE DA; BERESFORD CH; ABILDGAARD U; HUGHES PM; THEIN SL. (1 Apr 1993). A RECURRENT DELETION IN THE ANTITHROMBIN GENE, AT106-108(-6 BP), IDENTIFIED BY DNA HETERODUPLEX DETECTION. GENOMICS. 16:298-299. Author weblink DOI.
  • LANE DA; OLDS RJ; CONARD J; BOISCLAIR M; BOCK SC; HULTIN M; ABILDGAARD U; IRELAND H; et alTHOMPSON E; SAS G; HORELLOU MH; TAMPONI G; THEIN SL. (1 Dec 1992). PLEIOTROPIC EFFECTS OF ANTITHROMBIN STRAND 1C SUBSTITUTION MUTATIONS. JOURNAL OF CLINICAL INVESTIGATION. 90:2422-2433. Author weblink DOI.
  • Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR. (10 Nov 1992). Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Thromb Haemost. 68:563-569.
  • Lane DA; Olds RR; Thein SL. (Jun 1992). Antithrombin and its deficiency states. Blood Coagul Fibrinolysis. 3:315-341.
  • OLDS RJ; LANE DA; BOISCLAIR M; SAS G; BOCK SC; THEIN SL. (6 Apr 1992). ANTITHROMBIN BUDAPEST-3 - AN ANTITHROMBIN VARIANT WITH REDUCED HEPARIN AFFINITY RESULTING FROM THE SUBSTITUTION L99F. FEBS LETTERS. 300:241-246. Author weblink DOI.
  • OLDS RJ; LANE DA; CASO R; PANICO M; MORRIS HR; SAS G; DAWES J; THEIN SL. (1 Mar 1992). ANTITHROMBIN-III BUDAPEST - A SINGLE AMINO-ACID SUBSTITUTION (429PRO TO LEU) IN A REGION HIGHLY CONSERVED IN THE SERPIN FAMILY. BLOOD. 79:1206-1212. Author weblink.
  • Lane DA; Ryan K; Ireland H; Curtis JR; Nurmohamed MT; Krediet RT; Roggekamp MC; Stevens P; et alten Cate JW. (8 Feb 1992). Dermatan sulphate in haemodialysis. Lancet. 339:334-335.
  • Lane DA; Ireland H; Olds RJ; Thein SL; Perry DJ; Aiach M. (2 Dec 1991). Antithrombin III: a database of mutations. Thromb Haemost. 66:657-661.
  • OLDS RJ; LANE DA; IRELAND H; FINAZZI G; BARBUI T; ABILDGAARD U; GIROLAMI A; THEIN SL. (1 Dec 1991). A COMMON POINT MUTATION PRODUCING TYPE-1A ANTITHROMBIN-III DEFICIENCY - AT129 CGA TO TGA (ARG TO STOP). THROMBOSIS RESEARCH. 64:621-625. DOI.
  • Ryan KE; Lane DA; Flynn A; Shepperd J; Ireland HA; Curtis JR. (2 Sep 1991). Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost. 66:277-282.
  • Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; et alOlds R; Thein SL. (Sep 1991). Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin. Br J Haematol. 79:70-74.
  • DAWES J; MCLAREN M; FORBES C; BELCH JJF; LANE DA; BRAY B; MCEWEN J; HOUIN G; et alGIANESE F. (1 Sep 1991). THE PHARMACOKINETICS OF DERMATAN SULFATE MF701 IN HEALTHY-HUMAN VOLUNTEERS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 32:361-366. Author weblink.
  • OWEN MC; GEORGE PM; LANE DA; BOSWELL DR. (25 Mar 1991). P1 VARIANT ANTITHROMBINS GLASGOW (393 ARG TO HIS) AND PESCARA (393 ARG TO PRO) HAVE INCREASED HEPARIN AFFINITY AND ARE RESISTANT TO CATALYTIC CLEAVAGE BY ELASTASE - IMPLICATIONS FOR THE HEPARIN ACTIVATION MECHANISM. FEBS LETTERS. 280:216-220. Author weblink DOI.
  • IRELAND HA; BOISCLAIR MD; LANE DA; THOMPSON E; CURTIS J. (1 Jan 1991). HEMODIALYSIS AND HEPARIN - ALTERNATIVE METHODS OF MEASURING HEPARIN AND OF DETECTING ACTIVATION OF COAGULATION. CLINICAL NEPHROLOGY. 35:26-34. Author weblink.
  • CASO R; LANE DA; THOMPSON EA; OLDS RJ; THEIN SL; PANICO M; BLENCH I; MORRIS HR; et alFREYSSINET JM; AIACH M; RODEGHIERO F; FINAZZI G. (1 Jan 1991). ANTITHROMBIN VICENZA, ALA-384 TO PRO (GCA TO CCA) MUTATION, TRANSFORMING THE INHIBITOR INTO A SUBSTRATE. BRITISH JOURNAL OF HAEMATOLOGY. 77:87-92. Author weblink DOI.
  • OLDS RJ; LANE DA; FINAZZI G; BARBUI T; THEIN SL. (1 Dec 1990). A FRAMESHIFT MUTATION LEADING TO TYPE-1 ANTITHROMBIN DEFICIENCY AND THROMBOSIS. BLOOD. 76:2182-2186. Author weblink.
  • GANDRILLE S; AIACH M; LANE DA; VIDAUD D; MOLHOSABATIER P; CASO R; DEMOERLOOSE P; FIESSINGER JN; et alCLAUSER E. (5 Nov 1990). IMPORTANT ROLE OF ARGININE-129 IN HEPARIN-BINDING SITE OF ANTITHROMBIN-III - IDENTIFICATION OF A NOVEL MUTATION ARGININE-129 TO GLUTAMINE. JOURNAL OF BIOLOGICAL CHEMISTRY. 265:18997-19001. Author weblink.
  • LANE DA; RYAN K. (1 Aug 1990). THE IMPORTANCE OF ANTI-FACTOR XA AND ANTITHROMBIN ACTIVITIES OF LOW-MOLECULAR-WEIGHT HEPARINS. JOURNAL OF LABORATORY AND CLINICAL MEDICINE. 116:269-270. Author weblink.
  • Caso R; Lane DA; Thompson E; Zangouras D; Panico M; Morris H; Olds RJ; Thein SL; et alGirolami A. (15 Apr 1990). Antithrombin Padua. I: Impaired heparin binding caused by an Arg47 to his (CGT to CAT) substitution. Thromb Res. 58:185-190.
  • Boisclair MD; Lane DA; Wilde JT; Ireland H; Preston FE; Ofosu FA. (Apr 1990). A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol. 74:471-479.
  • Boisclair MD; Ireland H; Lane DA. (Mar 1990). Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev. 4:25-40.
  • Anastassiades E; Ireland H; Flynn A; Lane DA; Curtis JR. (1990). A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Nephrol Dial Transplant. 5:135-140.
  • Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR. (Dec 1989). A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Clin Nephrol. 32:290-296.
  • CASO R; LANE DA; THOMPSON E; ZANGOURAS D; PANICO M; MORRIS H; OLDS RJ; THEIN SL; et alGIROLAMI A. (1 Nov 1989). ANTITHROMBIN PADUA-I, DECREASED HEPARIN BINDING CAUSED BY A 47ARG TO HIS SUBSTITUTION ARISING FROM A CPG MUTATION. BRITISH JOURNAL OF HAEMATOLOGY. 73:440-440. Author weblink.
  • Lane DA; Ryan K. (Oct 1989). Heparin and low molecular weight heparin: is anti-factor Xa activity important?. J Lab Clin Med. 114:331-333.
  • Bray B; Lane DA; Freyssinet JM; Pejler G; Lindahl U. (15 Aug 1989). Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J. 262:225-232.
  • TONES MA; BOOTMAN MD; HIGGINS BF; LANE DA; PAY GF; LINDAHL U. (31 Jul 1989). THE EFFECT OF HEPARIN ON THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN RAT-LIVER MICROSOMES - DEPENDENCE ON SULFATE CONTENT AND CHAIN-LENGTH. FEBS LETTERS. 252:105-108. Author weblink DOI.
  • GORDGE MP; FAINT RW; RYLANCE PB; IRELAND H; LANE DA; NEILD GH. (30 Jun 1989). PLASMA D DIMER - A USEFUL MARKER OF FIBRIN BREAKDOWN IN RENAL-FAILURE. THROMBOSIS AND HAEMOSTASIS. 61:522-525. Author weblink.
  • Erdjument H; Lane DA; Panico M; Di Marzo V; Morris HR; Bauer K; Rosenberg RD. (15 Jun 1989). Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. Thromb Res. 54:613-619.
  • Lane DA; Erdjument H; Thompson E; Panico M; Di Marzo V; Morris HR; Leone G; De Stefano V; et alThein SL. (15 Jun 1989). A novel amino acid substitution in the reactive site of a congenital variant antithrombin. Antithrombin pescara, ARG393 to pro, caused by a CGT to CCT mutation. J Biol Chem. 264:10200-10204.
  • LANE DA. (7 Jun 1989). HEPARIN NEUTRALIZING PROTEINS IN BLOOD. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 556:453-455. Author weblink DOI.
  • LANE DA; TEW C; IRELAND H; FLYNN A; CURTIS J. (1989). HEPARIN AND LOW-MOLECULAR WEIGHT HEPARIN(OID)S AS ANTICOAGULANTS IN HEMODIALYSIS FOR CHRONIC-RENAL-FAILURE. 556:456-458.
  • Lane DA; Erdjument H; Flynn A; Di Marzo V; Panico M; Morris HR; Greaves M; Dolan G; et alPreston FE. (Jan 1989). Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis. Br J Haematol. 71:91-96.
  • Erdjument H; Lane DA; Ireland H; Di Marzo V; Panico M; Morris HR; Tripodi A; Mannucci PM. (22 Dec 1988). Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys. Thromb Haemost. 60:471-475.
  • Tew CJ; Lane DA; Thompson E; Ireland H; Curtis JR. (Nov 1988). Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222. Br J Haematol. 70:335-340.
  • THEIN SL; LANE DA. (1 Nov 1988). USE OF SYNTHETIC OLIGONUCLEOTIDES IN THE CHARACTERIZATION OF ANTITHROMBIN-III NORTHWICK-PARK (393 CGT-]TGT) AND ANTITHROMBIN-III GLASGOW (393 CGT-]CAT). BLOOD. 72:1817-1821. Author weblink.
  • BOURIN MC; OHLIN AK; LANE DA; STENFLO J; LINDAHL U. (15 Jun 1988). RELATIONSHIP BETWEEN ANTICOAGULANT ACTIVITIES AND POLYANIONIC PROPERTIES OF RABBIT THROMBOMODULIN. JOURNAL OF BIOLOGICAL CHEMISTRY. 263:8044-8052. Author weblink.
  • WILDE JT; THOMAS WEG; LANE DA; GREAVES M; PRESTON FE. (1 Jun 1988). ACQUIRED DYSFIBRINOGENEMIA MASQUERADING AS DISSEMINATED INTRAVASCULAR COAGULATION IN ACUTE-PANCREATITIS. JOURNAL OF CLINICAL PATHOLOGY. 41:615-618. Author weblink DOI.
  • Erdjument H; Lane DA; Panico M; Di Marzo V; Morris HR. (25 Apr 1988). Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow. J Biol Chem. 263:5589-5593.
  • Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR. (8 Apr 1988). Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222. Thromb Haemost. 59:240-247.
  • Lane DA; Flynn AM; Pejler G; Lindahl U; Choay J; Preissner K. (5 Dec 1987). Structural requirements for the neutralization of heparin-like saccharides by complement S protein/vitronectin. J Biol Chem. 262:16343-16348.
  • Erdjument H; Lane DA; Ireland H; Panico M; Di Marzo V; Blench I; Morris HR. (5 Oct 1987). Formation of a covalent disulfide-linked antithrombin-albumin complex by an antithrombin variant, antithrombin "Northwick Park". J Biol Chem. 262:13381-13384.
  • Lane DA; Lowe GD; Flynn A; Thompson E; Ireland H; Erdjument H. (Aug 1987). Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis. Br J Haematol. 66:523-527.
  • SOUTHAN C; THOMPSON E; LANE DA. (1 Apr 1987). DIRECT ANALYSIS OF PLASMA FIBRINOGEN-DERIVED FIBRINOPEPTIDES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - INVESTIGATION OF 9 CONGENITAL FIBRINOGEN ABNORMALITIES. BRITISH JOURNAL OF HAEMATOLOGY. 65:469-473. DOI.
  • LANE DA; FLYNN A; IRELAND H; ERDJUMENT H; SAMSON D; HOWARTH D; THOMPSON E. (1 Apr 1987). ANTITHROMBIN-III NORTHWICK-PARK - DEMONSTRATION OF AN INACTIVE HIGH MW COMPLEX WITH INCREASED AFFINITY FOR HEPARIN. BRITISH JOURNAL OF HAEMATOLOGY. 65:451-456. Author weblink DOI.
  • SOUTHAN C; THOMPSON E; LANE DA. (21 Oct 1986). DIRECT ANALYSIS OF PLASMA FIBRINOGEN-DERIVED FIBRINOPEPTIDES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - INVESTIGATION OF A-ALPHA-CHAIN N-TERMINAL HETEROGENEITY. THROMBOSIS AND HAEMOSTASIS. 56:193-197. Author weblink.
  • SOUTHAN C; THOMPSON E; LANE DA. (15 Jul 1986). DIRECT ANALYSIS OF PLASMA FIBRINOGEN-DERIVED FIBRINOPEPTIDES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY. THROMBOSIS RESEARCH. 43:195-204. Author weblink DOI.
  • IRELAND H; LANE DA; FLYNN A; ANASTASSIADES E; CURTIS J. (30 Apr 1986). THE ANTICOAGULANT EFFECT OF HEPARINOID ORG 10172 DURING HEMODIALYSIS - AN OBJECTIVE ASSESSMENT. THROMBOSIS AND HAEMOSTASIS. 55:271-275. Author weblink.
  • LANE DA; PEJLER G; FLYNN AM; THOMPSON EA; LINDAHL U. (25 Mar 1986). NEUTRALIZATION OF HEPARIN-RELATED SACCHARIDES BY HISTIDINE-RICH GLYCOPROTEIN AND PLATELET FACTOR-IV. JOURNAL OF BIOLOGICAL CHEMISTRY. 261:3980-3986. Author weblink.
  • LANE DA; FLYNN A; IRELAND H; ANASTASSIADES E; CURTIS J. (1 Jan 1986). ON THE EVALUATION OF HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN IN HEMODIALYSIS FOR CHRONIC-RENAL-FAILURE. HAEMOSTASIS. 16:38-47. Author weblink.
  • CONNAGHAN DG; FRANCIS CW; LANE DA; MARDER VJ. (1 Jan 1985). SPECIFIC IDENTIFICATION OF FIBRIN POLYMERS, FIBRINOGEN DEGRADATION PRODUCTS, AND CROSSLINKED FIBRIN DEGRADATION PRODUCTS IN PLASMA AND SERUM WITH A NEW SENSITIVE TECHNIQUE. BLOOD. 65:589-597. Author weblink.
  • LANE DA. (1 Jan 1985). PLATELET-DERIVED HEPARIN NEUTRALIZING PROTEINS. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 192:427-438. Author weblink.
  • ANASTASSIADES E; LANE DA; IRELAND H; FLYNN A; CURTIS J. (1 Jan 1985). OBJECTIVE ASSESSMENT OF A LOW-MOLECULAR WEIGHT HEPARIN IN HEMODIALYSIS. KIDNEY INTERNATIONAL. 28:318-318. Author weblink.
  • SOUTHAN C; LANE DA; KNIGHT I; IRELAND H; BOTTOMLEY J. (1 Jan 1985). FIBRINOGEN MANCHESTER - DETECTION OF A HETEROZYGOUS PHENOTYPE IN THE INTRAPLATELET POOL. BIOCHEMICAL JOURNAL. 229:723-730. Author weblink.
  • RYLANCE PB; GORDGE MP; IRELAND H; LANE DA; WESTON MJ. (1 Jan 1985). HEMODIALYSIS WITH PROSTACYCLIN (EPOPROSTENOL) ALONE. PROCEEDINGS OF THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION. 21:281-286. Author weblink.
  • LANE DA; IRELAND H; CURTIS J. (1 Jan 1985). HEPARIN DOSAGE DURING HEMODIALYSIS - REPLY. JOURNAL OF LABORATORY AND CLINICAL MEDICINE. 105:139-140. Author weblink.
  • HUGHES RD; LANE DA; IRELAND H; LANGLEY PG; GIMSON AES; WILLIAMS R. (1 Jan 1985). FIBRINOGEN DERIVATIVES AND PLATELET ACTIVATION PRODUCTS IN ACUTE AND CHRONIC LIVER-DISEASE. CLINICAL SCIENCE. 68:701-707.
  • SOUTHAN C; LANE DA; BODE W; HENSCHEN A. (1 Jan 1985). THROMBIN-INDUCED FIBRINOPEPTIDE RELEASE FROM A FIBRINOGEN VARIANT (FIBRINOGEN SYDNEY-I) WITH AN A-ALPHA-ARG-16-]HIS SUBSTITUTION. EUROPEAN JOURNAL OF BIOCHEMISTRY. 147:593-600. Author weblink.
  • CARNEY JA; KNIGHT I; LANE DA. (1 Jan 1985). A SENSITIVE LATEX SLIDE ASSAY FOR FIBRIN(OGEN) FRAGMENT-E. CLINICA CHIMICA ACTA. 147:173-177. Author weblink DOI.
  • SOUTHAN C; THOMPSON E; PANICO M; ETIENNE T; MORRIS HR; LANE DA. (1 Jan 1985). CHARACTERIZATION OF PEPTIDES CLEAVED BY PLASMIN FROM THE C-TERMINAL POLYMERIZATION DOMAIN OF HUMAN-FIBRINOGEN. JOURNAL OF BIOLOGICAL CHEMISTRY. 260:3095-3101. Author weblink.
  • LANE DA; IRELAND H; KNIGHT I; WOLFF S; KYLE P; CURTIS J. (1 Jan 1984). THE SIGNIFICANCE OF FIBRINOGEN DERIVATIVES IN PLASMA IN HUMAN RENAL-FAILURE. BRITISH JOURNAL OF HAEMATOLOGY. 56:251-260. Author weblink DOI.
  • LANE DA; DENTON J; FLYNN AM; THUNBERG L; LINDAHL U. (1 Jan 1984). ANTICOAGULANT ACTIVITIES OF HEPARIN OLIGOSACCHARIDES AND THEIR NEUTRALIZATION BY PLATELET FACTOR-4. BIOCHEMICAL JOURNAL. 218:725-732. Author weblink.
  • LANE DA; IRELAND H; WOLFF S; RANASINGHE E; DAWES J. (1 Jan 1984). DETECTION OF ENHANCED INVIVO PLATELET ALPHA-GRANULE RELEASE IN DIFFERENT PATIENT GROUPS - COMPARISON OF BETA-THROMBOGLOBULIN, PLATELET FACTOR-4 AND THROMBOSPONDIN ASSAYS. THROMBOSIS AND HAEMOSTASIS. 52:183-187. Author weblink.
  • LANE DA; MARKWICK J; THOMPSON E; IRELAND H. (1 Jan 1984). EXPERIMENTAL-EVIDENCE FOR RENAL CATABOLISM OF FIBRIN FRAGMENT BETA-15-42. THROMBOSIS RESEARCH. 33:571-581. Author weblink DOI.
  • IRELAND H; LANE DA; CURTIS J. (1 Jan 1984). OBJECTIVE ASSESSMENT OF HEPARIN REQUIREMENTS FOR HEMODIALYSIS IN HUMANS. JOURNAL OF LABORATORY AND CLINICAL MEDICINE. 103:643-652. Author weblink.
  • DENTON J; LANE DA; THUNBERG L; SLATER AM; LINDAHL U. (1 Jan 1983). BINDING OF PLATELET FACTOR-4 TO HEPARIN OLIGOSACCHARIDES. BIOCHEMICAL JOURNAL. 209:455-460. Author weblink.
  • LANE DA; SOUTHAN C; IRELAND H; THOMPSON E; KEHL M; HENSCHEN A. (1 Jan 1983). DELAYED RELEASE OF AN ABNORMAL FIBRINOPEPTIDE-A FROM FIBRINOGEN MANCHESTER - EFFECT OF THE A-ALPHA 16 ARG-] HIS SUBSTITUTION UPON FIBRIN MONOMER POLYMERIZATION AND THE IMMUNOLOGICAL CROSSREACTIVITY OF THE PEPTIDE. BRITISH JOURNAL OF HAEMATOLOGY. 53:587-597. Author weblink DOI.
  • LANE DA; WOLFF S; IRELAND H; GAWEL M; FOADI M. (1 Jan 1983). ACTIVATION OF COAGULATION AND FIBRINOLYTIC SYSTEMS FOLLOWING STROKE. BRITISH JOURNAL OF HAEMATOLOGY. 53:655-658. Author weblink DOI.
  • SOUTHAN C; KEHL M; HENSCHEN A; LANE DA. (1 Jan 1983). FIBRINOGEN MANCHESTER - IDENTIFICATION OF AN ABNORMAL FIBRINOPEPTIDE-A WITH A C-TERMINAL ARGININE-]HISTIDINE SUBSTITUTION. BRITISH JOURNAL OF HAEMATOLOGY. 54:143-151. Author weblink DOI.
  • LANE DA; MARKWICK J; THOMPSON E; IRELAND H. (1 Jan 1983). EXPERIMENTAL-EVIDENCE FOR RENAL CATABOLISM OF FIBRINOGEN FRAGMENT BETA-15-42. THROMBOSIS AND HAEMOSTASIS. 50:298-298. Author weblink.
  • LANE DA; SIODLAK M; THOMPSON E; ALLENMERSH TG. (1 Jan 1982). CLEARANCE OF HUMAN DESAMINOTYROSYL FIBRINOPEPTIDE A FROM THE RAT CIRCULATION - ROLE OF KIDNEY AND PROTEOLYTIC-ENZYMES. THROMBOSIS RESEARCH. 26:73-82. Author weblink DOI.
  • LANE DA; IRELAND H; WOLFF S; GRANT R; JENNINGS S; ALLENMERSH T. (1 Jan 1982). PLASMA-CONCENTRATIONS OF FIBRINOPEPTIDE-A, FIBRINOGEN FRAGMENT-BETA-1-42 AND BETA-THROMBOGLOBULIN FOLLOWING TOTAL HIP-REPLACEMENT. THROMBOSIS RESEARCH. 26:111-118. Author weblink DOI.
  • LANE DA; IRELAND H; THOMPSON E; FROST TJ; CUDDIGAN B. (1 Jan 1982). 2 MORE ABNORMAL FIBRINOGENS (LONDON-III AND SYDNEY) WITH IMPAIRED FIBRINOPEPTIDE RELEASE. THROMBOSIS RESEARCH. 28:821-824. Author weblink DOI.
  • IRELAND H; LANE DA; WOLFF S; FOADI M. (1 Jan 1982). INVIVO PLATELET-RELEASE IN MYELOPROLIFERATIVE DISORDERS. THROMBOSIS AND HAEMOSTASIS. 48:41-45. Author weblink.
  • LANE DA. (1 Jan 1981). FIBRINOGEN DERIVATIVES IN PLASMA. BRITISH JOURNAL OF HAEMATOLOGY. 47:329-335. Author weblink DOI.
  • MACGREGOR IR; LANE DA; KAKKAR VV. (1 Jan 1980). THE HEPARIN-ACCELERATED NEUTRALIZATION OF BOVINE ALPHA-THROMBINS AND BETA-THROMBINS BY ANTI-THROMBIN-III. BIOCHIMICA ET BIOPHYSICA ACTA. 632:131-137. Author weblink DOI.

Conferences

  • Crawley JTB; Zanardelli S; Chion C; Lane DA. The central role of thrombin in hemostasis. 22nd Congress of the International-Society-on Thrombosis-and-Haemostasis. 5:95-101. (Jul 2007).
  • Lane DA. The protein C anticoagulant pathway: new insights. 2nd International Symposium on Womens Health Issues in Thrombosis and Haemostasis, 2 Feb 2007 - 4 Feb 2007. 119:S6-S7. PERGAMON-ELSEVIER SCIENCE LTD (1 Jan 2007). Author weblink DOI.
  • Lane DA. Regulation of thrombin. IUBMB 50th Anniversary Symposium. 272:404-404. (Jul 2005).
  • LANE DA. HEPARIN NEUTRALIZING PROTEINS IN BLOOD. CONF ON STRUCTURE AND ACTIVITIES OF HEPARIN AND RELATED POLYSACCHARIDES, 3 Nov 1987 - 5 Nov 1987. 556:453-455. NEW YORK ACAD SCIENCES (1 Jan 1989). Author weblink DOI.
  • LANE DA; TEW C; IRELAND H; FLYNN A; CURTIS J. HEPARIN AND LOW-MOLECULAR WEIGHT HEPARIN(OID)S AS ANTICOAGULANTS IN HEMODIALYSIS FOR CHRONIC-RENAL-FAILURE. CONF ON STRUCTURE AND ACTIVITIES OF HEPARIN AND RELATED POLYSACCHARIDES, 3 Nov 1987 - 5 Nov 1987. 556:456-458. NEW YORK ACAD SCIENCES (1 Jan 1989). Author weblink DOI.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook